Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Sabarinath Venniyil Radhakrishnan MD
Assistant Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Froedtert East Clinics
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
09/1996 - 01/2001 M.B.B.S, University of Kerala, Trivandrum, India
03/2001 - 03/2002 Internship, University of Kerala, Trivandrum, India
03/2003 - 03/2006 MD General Medicine, University of Kerala, Trivandrum, India

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/2010 - 06/2013 Internal Medicine Residency, Internal Medicine (Program Director: Dr. Stephen Greenberg), Louisiana State University Health Sciences Center Shreveport, LA
07/2013 - 06/2017 Hematology/Oncology Fellowship, Hematology & Oncology (Program Director: Dr. Martha Glenn), Huntsman Cancer Institute/University of Utah, UT

FACULTY APPOINTMENTS:
08/2019 - 06/2020 Assistant Professor, Hematology & Hematological Malignancies, University of Utah, UT
07/2021 - Present Assistant Professor, Medicine, Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
08/2017 - 07/2019 Visiting Instructor, Hematology and Hematological Malignancies, University of Utah, UT

RESEARCH ADMINISTRATIVE APPOINTMENTS:
2010 - 2014 Laboratory of Gerhard C Hildebrandt MD, Louisiana State University Shreveport & University of Utah, UT
2015 - 2020 Laboratory of Djorde Atanackovic MD, University of Utah/Huntsman Cancer Institute, UT
2021 - Present Principal Investigator, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Internal Medicine
10/2013
10/2023
Medical Oncology
12/2016
12/2026
Hematology
12/2016
12/2026
   
Licensure
Number Issue DateExpiration
Travancore-Cochin Medical Council (India)
2002
None
Medical License in Louisiana
2010
2013
Medical License in Utah
2013
2021
WI license
2021
2025
    

AWARDS AND HONORS:
2012 Abstract Achievement Award, American Society of Hematology (ASH)
2015 Joseph M Quagliana MD & Paula Quagliana Fellow Research Award, University of Utah
2017 - 2019 Pfizer Fellowship Award in Immuno-oncology Research, American Association for Cancer Research (AACR)
2022 - 2024 New Investigator Award , American Society for Transplantation and Cellular Therapy (ASTCT)

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society of Hematology (ASH) (Member)
International Myeloma Society (IMS) (Member)
American Society for Transplantation and Cellular Therapy (ASTCT) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
Hematology
Clinical Case Reports
Scientific Reports
Oncotarget
Annals of Medicine
Respiration
Journal for Immunotherapy of Cancer
Transplantation and Cellular Therapy
Cytotherapy
Journal of Clinical Medicine
Cancer Treatment Reviews
Blood
BMC Cancer
Biochemical Society Transactions

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
BCMA targeted CAR T cells armored with a mechanism to block the “Don’t Eat me” pathway in macrophages.
Source:
Paula & Rodger Riney Foundation grant
Role & Effort:
Principal Investigator
PI:
Radhakrishnan, Sabarinath
Dates:
06/15/2022 - 06/14/2024
Direct Funds:
$1,120,193
  
Title:
Targeting trogocytosis pathway to overcome CAR T cell failure $100,000 in Multiple Myeloma
Source:
American Society for Transplantation and Cellular Therapy (ASTCT)
Role & Effort:
Principle Investigator
PI:
Radhakrishnan, Sabarinath
Dates:
07/2022 - 06/2024
Direct Funds:
$100,000 (New Investigator Award)
  
Non-Peer Review
Title:
Start up grant
Source:
Medical College of Wisconsin
Role & Effort:
Principal Investigator
PI:
Sabarinath Venniyil Radhakrishnan
Dates:
07/01/2021 - 06/30/2026
Direct Funds:
$550,000
  
Prior
Peer Review
Title:
Chimeric antigen receptor (CAR) T cell therapy for multiple myeloma
Source:
American Association for Cancer Research
Role & Effort:
Principle Investigator
PI:
Radhakrishnan, Sabarinath
Dates:
08/2017 - 07/2019
Direct Funds:
$110,000
  
Non-Peer Review
Title:
Chimeric Antigen Receptor T cells targeting CD229: A new treatment modality for multiple myeloma
Source:
Quagliana Fellow Research Award, University of Utah
Role & Effort:
FEL
Dates:
07/2015 - 06/2016
Direct Funds:
$10,000
  
Title:
Development of a high affinity antibody against CD229 for the treatment of Multiple Myeloma
Source:
American Cancer Society
Role & Effort:
Principle Investigator
PI:
Radhakrishnan, Sabarinath
Dates:
01/2019 - 06/2020
Direct Funds:
$30,000 (Institutional Research Grant )
  
Title:
Development of an antibody drug conjugate targeting CD229 for the treatment of Multiple Myeloma
Source:
Huntsman Cancer Institute
Role & Effort:
Principle Investigator
PI:
Radhakrishnan, Sabarinath
Dates:
07/2019 - 06/2021
Direct Funds:
$60,000 (Cancer Center Support grant, Experimental Therapeutics)
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
International
Rapid Process for the Generation of Functional Chimeric Antigen Receptors Against Novel Targets., European Society for Blood and Marrow Transplantation (EBMT) annual meeting, Marseilles, 03/2017
A high throughput process for generation and characterization of functional chimeric antigen receptors against novel targets, University of Wurzburg, 03/2017
Cancer Immunotherapy: Chimeric Antigen Receptor T cells., Seminar on Virology & Immunology, Trivandrum Medical College Platinum Jubilee, Kerala, India, 08/27/2022
Cellular therapies in multiple myeloma., International Conference on Multidisciplinary Management of Common Cancers, Cancer Control & Research Society, Kerala, India, 03/08/2024
 
National
Mediation of LA-4 lung epithelial cell injury by allo reactive donor T cells., American Society for Clinical Oncology (ASCO), annual meeting, Chicago, IL, 06/2011
The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases the Severity of Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation., American Society of Hematology (ASH) annual meeting, Atlanta, GA, 12/2012
Azithromycin induces the expansion of regulatory T cells and diminishes allo reactive T cell proliferation in vitro and in vivo., American Society for Blood and Marrow Transplantation (ASBMT) annual meeting, Salt Lake City, UT, 02/2013
A high-throughput process for the development and characterization of chimeric antigen receptors (CARs)., American Association of Cancer Research (AACR) annual meeting, Washington DC, 04/2017
A novel CAR T cell therapy for multiple myeloma., Immunology, Inflammation & Infectious Disease Summer symposium, Park City, Utah,, 08/2017
A Novel High Throughput Process for Generation and Characterization of Chimeric Antigen Receptor (CAR) T Cells., 4. A Novel High Throughput Process for Generation and Characterization of Chimeric Antigen Receptor (CAR) T Cells., Houston, TX, 09/2017
Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma., American Society of Hematology (ASH) annual meeting, Atlanta, GA, 12/2017
Dimethyl Oxalyl Glycine a Prolyl Hydroxylase Inhibitor Decreases Early Gastrointestinal Gvhd Via Two Independent Pathways of Apoptosis after Allogeneic Hematopoietic Cell Transplantation., American Society of Hematology (ASH) annual meeting, San Diego, CA, 12/2018
CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma., American Association of Cancer Research (AACR) annual meeting, Philadelphia, PA, 04/2020
Sabarinath Venniyil Radhakrishnan, PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis, American Society of Hematology (ASH) annual meeting, San Diego, CA, 12/2024
Sabarinath Venniyil Radhakrishnan, CD47-CD138 bispecific antibody exhibits selective targeting of multiple myeloma, American Society of Hematology (ASH) annual meeting, San Diego, CAA, 12/2024
 

LINK TO LAB WEBSITE:
https://www.mcw.edu/departments/medicine/divisions/hematology-oncology-cancer/research/radhakrishnan-laboratory


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. The role of surface molecule CD229 in Multiple Myeloma. Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D. Clin Immunol. 2018 Oct 13. pii: S1521-6616
2. Elotuzumab as a Novel Anti-Myeloma Immunotherapy. Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Human Vaccines and Immunotherapeutics. Volume 13, issue 8, May 2017
3. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. Atanackovic D, Luetkens T, Radhakrishnan S, Kroeger N, Current Cancer Drug Targets. 2017;17(9):839-845
4. Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D. Oncoimmunology. 2017 Mar 28;6(5):e1308618
5. Current Strategies for the Immunotherapy of Multiple Myeloma. Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D. Oncology (Williston Park). 2017 Jan 15;31(1).
6. Immunotherapies targeting CD38 in Multiple Myeloma. Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Oncoimmunology. 2016 Aug 5;5(11).
7. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Br J Haematol 2016 Mar 20;172(5):685-98
8. A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population. Radhakrishnan SV and Hildebrandt GC. Curr Hematol Malig Rep. 2015 Mar;10(1):8-17
9. Restricting CAR T Cell Trafficking Expands Targetable Antigen Space. Morales EA, Dietze KA, Baker JM, Wang A, Avila SV, Iglesias F, Radhakrishnan SV, Mause EV, Olson ML, Sun W, Rosati E, Chidester SL, Iraguha T, Fan X, Atanackovic D, Luetkens T. bioRxiv [Preprint]. 2024 Feb 11:2024.02.08.579002.
10. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P. Blood Adv. 2022 Apr 26;6(8):2466-2470.
 
Books, Chapters, and Reviews
1. Chronic graft versus host disease: Clinical Manual of Blood and Bone Marrow Transplantation. Radhakrishnan SV and Couriel DR, June 2017
2. Red cell destruction disorders: Hematology Board Review: Blueprint Study Guide and Q&A. Radhakrishnan SV and Parker CJ, May 2018
 
Non-Refereed Journal Publications/Original Papers
1. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER , Olson M, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D. Nat Commun. 2020 Feb 7;11(1):798.
2. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. Palaniyandi S, Kumari R, Radhakrishnan SV, Strattan E, Hakim N, Munker M, Kesler MV, Hildebrandt GC. Transplantation. 2020 Jun 29.
3. A phase 1 study of intravenous busulfan as a conditioning regimen for Multiple Myeloma. Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot GJ. Cell Transplant. 2019 Dec;28(12):1624-1631.
4. In Vivo Vaccination Effect in Multiple Myeloma Patients Treated with the Monoclonal Antibody Isatuximab. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Leukemia. 2020 Jan;34(1):317-321.
5. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/ NFKB/MAPK activation. Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T. Oncotarget. 2017 Jul 25;8(30):49253-49263
6. Pomalidomide as Consolidation Therapy after Salvage Autologous Stem Cell Transplant. Steinbach M, Luetkens T, Vinik K, Radhakrishnan SV , Atanackovic D. J J Bone Stem Res. 2016, 2(2): 015
7. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft versus host disease in a murine model of allogeneic hematopoietic cell transplantation. Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC. Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8.
8. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Nat Med. 2014 Jun;20(6):648-54.
9. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC. PLoS One. 2013 Apr 15;8(4).
10. Beneficiary Effect of Autologous Hematopoietic Cell Transplantation in Idiopathic Ulcerative Dermatitis C57BL/6 Mice. Palaniyandi S, Huber E, Radhakrishnan SV, Orchard EA, Hildebrandt GC. J Bone Marrow Res. 2: 139
11. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Sci Transl Med. 2023 Jul 19;15(705)
12. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. Haematologica. 2023 Aug 31.
13. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Am J Hematol. 2022 Dec;97(12):E451-E453.
14. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Am J Hematol. 2022 Jul;97(7):E276-E280.
15. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Olson M, Vander Mause E, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T. Leukemia. 2022 Jul;36(7):1943-1946.
 
Patents
1. CD229 CAR T Cells and Methods of Use Thereof. Luetkens T, Atanackovic D, Radhakrishnan SV (Published). Patent No.WO2018017708A1. 01/25/2018
2. Compositions that target CD47 and CD138 and methods of making and using the same. Inventors: Radhakrishnan SV, Figueroa MG. U.S. Provisional Application No. 63/715,115. Filed Nov1, 2024
3. Self-Regulated Chimeric Antigen Receptor T cells and Methods of Preparing and using the same. Inventor: Radhakrishnan SV. U.S. Provisional Application No. 63/643,548. Filed May 7, 2024